（31 March, 2020, Shanghai）March 30 2020,Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its annual results for the year 2019 ("the reporting period").
During the reporting period：
· The revenue increased by 14.72% as compared to 2018 to RMB 28,585 million;
· The net profit amounted to RMB 3,744 million, representing a respective increase of 23.96%;
· The net profit attributable to shareholders of the listed company amounted to RMB 3,322 million, representing a respective increase of 22.66%.
· The cash flow from operating activities continued to rise. Net cash flow from operating activities amounted to RMB 3,222 million, representing an increase of 9.23% as compared to 2018.
Wu Yifang, President and CEO of Fosun Pharma, expressed that "2019 marks a crucial period for the pharmaceutical industry to experience comprehensive transformation. On the basis of properly carrying out the existing business and industrial upgrade, Fosun Pharma is firmly committed to the path of innovation and international development. Focusing on unmet medical needs, it continuously improved its product competitiveness and brand strength, persistently enhanced its capability of innovation, integration and international development, and conducted efficient operations, thereby maintaining the balanced growth of its principal businesses. We believe that our efforts in innovation will help Fosun Pharma realize its innovation transformation. The steady international-oriented development will make us more competitive internationally in terms of operation standards and market expansion."
Revenue for core products grew steadily and deeply cultivated the whole-industry chain of healthcare industry
The business areas of Fosun Pharma cover the whole-industry chain of pharmaceutical and healthcare. Its business development is based on China while Fosun Pharma actively conducts global layouts. In 2019, the core business of Fosun Pharma,pharmaceutical manufacturing and R&D segment, maintained stable growth and recorded segment operating revenue of RMB 21,766 million, an increase by 16.51% as compared to 2018.